Premium
Fertility of long‐term male survivors of acute lymphoblastic leukemia diagnosed during childhood
Author(s) -
Byrne Julianne,
Fears Thomas R.,
Mills James L.,
Zeltzer Lonnie K.,
Sklar Charles,
Meadows Anna T.,
Reaman Gregory H.,
Robison Leslie L.
Publication year - 2004
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.10449
Subject(s) - medicine , fertility , cohort , fertility preservation , pregnancy , late effect , pediatrics , young adult , cohort study , radiation therapy , gynecology , population , environmental health , biology , genetics
Fertility impairments among men treated during childhood for cancer are known to occur after some, but not all, types of anti‐cancer therapy. This is the first study to evaluate proven fertility among adult male survivors of childhood acute lymphoblastic leukemia (ALL). In a retrospective cohort study, proven fertility (ever fathered a pregnancy) was evaluated by self‐report among 213 men treated for ALL before age 18 on protocols of the Children's Cancer Group (CCG). Controls (N = 145) were drawn from among male siblings. Overall, with a proportional hazards analysis, proven fertility of male survivors was not different from that of controls (relative fertility (RF) = 0.95, 95% CI 0.63–1.43). However, married men treated before age 10 with high dose (24 cGy) cranial radiotherapy (RT), without spinal RT, had only 9% of the fertility of controls (Relative risk, RR = 0.09, 95% CI 0.01–0.82). High dose cranial RT at older ages was not associated with a statistically significant fertility deficit (RR = 0.56, 95% CI 0.25–1.28). In this first study of proven fertility among men treated for childhood leukemia, the majority of survivors showed no evidence of fertility impairment compared to controls. However, men treated at a young age with high dose cranial RT may have impaired fertility. These results suggest that further investigation of men with these treatments is needed to confirm and extend these findings. © 2003 Wiley‐Liss, Inc.